Results
1 -
10 of
12Cancer Therapeutic Applications of ENOX2 Proteins, ECTO-NOX Proteins Diarylsulfonylureas : new anticancer agents with novel activities, toxicities and mechanism of action, Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy Hormone- and growth factor-stimulated NADH oxidase, Journal of Bioenergetics and Biomembranes Phase II study of sulofenur (LY 186641), Investigational New Drugs Golgi apparatus respond to the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-Nu2032-(4-chlorophenyl)urea (LY 181984) in sulfonylurea-susceptible but not in resistant cell lines, Protoplasma Mechanism of killing of HeLa cells by the antitumor sulfonylurea, N-(4-methylphenylsulfonyl)-Nu2032-(4-chlorophenyl)urea (LY 181984), Protoplasma Response of NADH oxidation and growth in K-562 cells to the antitumor sulfonylurea, N-(4-methylphenylsulfonyl)-Nu2032-(4-chlorophenyl)urea (LY181984), Protoplasma Inhibition of the NADH oxidase activity of plasma membranes isolated from xenografts and cell lines by the antitumor sulfonylurea, N-(4-methylphenylsulfonyl)-Nu2032-(4-chlorophenyl)urea (LY 181984) correlates with drug susceptibility of growth, Protoplasma Monoclonal antibody to a cancer-specific and drug-responsive hydroquinone (NADH) oxidase from the sera of cancer patients, Cancer Immunology, Immunotherapy A Circulating Form of NADH Oxidase Activity Responsive to the Antitumor Sulfonylurea N-4-(methylphenylsulfonyl)-Nu2032-(4-chlorophenyl)urea (LY181984) Specific to Sera from Cancer Patients, Journal of Bioenergetics and Biomembranes